Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
[allergic bronchopulmonary aspergillosis]
Allergic
bronchopulmonary
aspergillosis
(
ABPA
)
is
a
severe
complication
in
patients
with
cystic
fibrosis
(
CF
)
,
resulting
in
deterioration
of
lung
function
and
impairment
of
overall
prognosis
.
Standard
therapy
consists
of
high
dosage
,
long
-term
corticosteroid
treatment
.
This
carries
the
risk
of
serious
side
effects
such
as
immune
suppression
,
diabetes
and
osteoporosis
.
Antifungal
drugs
such
as
itraconazole
may
cause
interactions
with
other
drugs
and
drug
levels
need
to
be
monitored
.
Omalizumab
treatment
has
been
tried
in
several
case
studies
.
This
was
a
retrospective
study
of
six
patients
(
four
female
,
two
male
,
age
4
-
33
years
old
)
with
CF
and
ABPA
treated
with
omalizumab
within
an
observation
period
of
7
.
5
years
.
All
patients
showed
clinical
and
laboratory
stability
or
even
an
improvement
within
the
treatment
and
post-treatment
observation
period
,
although
omalizumab
therapy
was
less
effective
in
patients
with
progressed
lung
disease
and
long
-term
ABPA
.
Side
effects
of
systemic
steroids
were
reduced
.
Omalizumab
has
the
potential
to
be
an
additional
and
solitary
treatment
option
in
patients
with
CF
and
ABPA
.
Early
onset
treatment
may
be
beneficial
and
patients
with
early
stage
of
lung
disease
seem
to
benefit
more
.
